BRAIN Biotech AG | The Big Conversation | Lukas Linnig, CFO Financial Frontiers: Unveiling Corporate Insights & Market Trends with seat11a.com

Welcome to seat11a, in today’s podcast we are presenting Lukas Linnig, CFO at Brain Biotech AG

Join Lukas in the Big Conversation.



Lukas will guide you through the following topics:

Changes CFO has already initiated

In layman terms: what does BRAIN?

What sets BRAIN apart from other Biotech companies?

Influence biotechnology can take on society

Biggest upcoming value drivers for BRAIN shareholders

Talking about Genome Engineering - the BRAIN Engineered Cas

Current financial situation - sufficient to think bold on BEC?

Focusing on growth only or is profitability also a target?

Mid-term financial targets?

How to attract and retain key employees

Importance of ESG 

What´s most exciting and what keeps CFO busy at night?



Company Profile

BRAIN Biotech AG (“BRAIN”) is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. 



BRAIN is the parent company of the BRAIN Group. 



Two pillars form BRAIN Group’s business: 



The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company’s own highly innovative products. 



In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.



The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. 



Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry. 



The BRAIN Group has its own production facilities in Germany, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group.



Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).





----------------------------

▶️ Visit us: https://seat11a.com/

----------------------------

▶️ Other videos:

Elevator Pitches: https://seat11a.com/media-type/elevator-pitch/

Company Presentations: https://seat11a.com/media-type/presentation/

Financial Results: https://seat11a.com/media-type/financials/

The Big Conversations: https://seat11a.com/media-type/conversation/

ESG Topics: https://seat11a.com/media-type/esg/

Product Highlights: https://seat11a.com/media-type/products/



-----------------------------

▶️ About seat11a:

Seat11a is the next-generation roadshow for listed companies. We democratize financial intelligence by offering listed companies an investor video platform to address their message to Institutional and Professional Investors anywhere, anytime.

-----------------------------

▶️ For business inquiries: info@seat11a.com

-----------------------------









✅ Disclaimer:

this publication is just for informational purposes only – it is not considered to give any investment advice! You agree to www.seat11a.com/legal/ and www.seat11a.com/imprint/